GE HLTHCARE INC
PharmaGE HLTHCARE INC is a pharmaceutical company focused on Neurology. Key products include FLYRCADO.
Upcoming FDA Decisions
Full Calendar →GE HLTHCARE INC's Key Drugs
GE HLTHCARE INC's core commercial portfolio centers on FLYRCADO, DATSCAN, spanning Neurology — its most strategically important drugs approved in the last 15 years.
GE HLTHCARE INC's Recent FDA Approvals
GE HLTHCARE INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
GE HLTHCARE INC's Therapeutic Areas
GE HLTHCARE INC's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GE HLTHCARE INC's Top Competitors
GE HLTHCARE INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GE HLTHCARE INC Pipeline Snapshot
Active clinical trials for GE HLTHCARE INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FLYRCADO leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling